Patent Application: Vaccine for Bordetella pertussis using antigen peptides

This document is a published patent application from the USPTO detailing a novel vaccine composition for Bordetella pertussis. The application, filed on September 15, 2023, and published as US20260083833A1, focuses on using Bordetella pertussis antigen peptides to generate CD4+ T cells, which are critical for sustained immunity against the bacterium. The invention aims to prevent infection by targeting specific antigen peptides processed and presented on MHC Class II molecules.

This patent application does not impose any immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in vaccine technology for pertussis. Pharmaceutical companies and researchers in the infectious disease and vaccine development space should note this application as it may inform future product development or intellectual property strategies. No penalties are associated with this filing; it is a notification of an invention disclosure.